PMID- 17389779
OWN - NLM
STAT- MEDLINE
DCOM- 20071023
LR  - 20151119
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 74
IP  - 5
DP  - 2007
TI  - Proton pump inhibitor improves breath marker in moderate asthma with 
      gastroesophageal reflux disease.
PG  - 558-64
AB  - BACKGROUND: Gastroesophageal reflux disease (GERD) influences the symptoms of 
      asthma with acid and oxidative stress. OBJECTIVES: The purpose of this study was 
      to determine the usefulness of measurement of the acid stress marker pH and the 
      oxidative stress marker 8-isoprostane by exhaled breath condensate in proton pump 
      inhibitor (PPI) therapy effect on moderate asthma patients with GERD. METHODS: 
      The pH and the concentration of 8-isoprostane were measured in the exhaled breath 
      condensate of patients with moderate asthma (n = 36) and healthy subjects (n = 
      26). Two months of PPI therapy (lansoprazole at 30 mg/day) were done in the 
      asthma patients with (n = 13) or without (n = 13) GERD according to a 
      questionnaire for the diagnosis of reflux disease, and exhaled markers were 
      measured. RESULTS: The pH was lower (7.3 +/- 0.3) and the 8-isoprostane level was 
      higher (27.7 +/- 2.3) in the asthma patients than in the healthy control subjects 
      (pH 7.5 +/- 0.2 and 8-isoprostane 6.6 +/- 1.2). Two months of PPI therapy 
      improved the pH (from 7.2 +/- 0.1 to 7.3 +/- 0.1) and the 8-isoprostane 
      concentration (from 32.7 +/- 3.4 to 19.2 +/- 3.4) in the asthma patients with 
      GERD, along with improvement of GERD symptoms. However, these markers did not 
      change in the asthma patients without GERD. CONCLUSIONS: Measurement of the pH 
      and 8-isoprostane level of exhaled breath condensate may be useful to evaluate 
      the influence of GERD on asthma, as well as to determine the timing of 
      intermittent PPI therapy.
CI  - Copyright 2007 S. Karger AG, Basel.
FAU - Shimizu, Yasuo
AU  - Shimizu Y
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Gunma, Japan. yasuos@med.gunma-u.ac.jp
FAU - Dobashi, Kunio
AU  - Dobashi K
FAU - Zhao, Jian Jun
AU  - Zhao JJ
FAU - Kawata, Tadayoshi
AU  - Kawata T
FAU - Ono, Akihiro
AU  - Ono A
FAU - Yanagitani, Noriko
AU  - Yanagitani N
FAU - Kaira, Kyoichi
AU  - Kaira K
FAU - Utsugi, Mitsuyoshi
AU  - Utsugi M
FAU - Hisada, Takeshi
AU  - Hisada T
FAU - Ishizuka, Tamotsu
AU  - Ishizuka T
FAU - Mori, Masatomo
AU  - Mori M
LA  - eng
PT  - Journal Article
DEP - 20070327
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Biomarkers)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*pharmacology/therapeutic use
MH  - Asthma/drug therapy/*epidemiology
MH  - Biomarkers/analysis
MH  - Breath Tests
MH  - Comorbidity
MH  - Dinoprost/analogs & derivatives/analysis
MH  - Female
MH  - Gastroesophageal Reflux/*epidemiology
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress
MH  - *Proton Pump Inhibitors
EDAT- 2007/03/29 09:00
MHDA- 2007/10/24 09:00
CRDT- 2007/03/29 09:00
PHST- 2006/10/23 00:00 [received]
PHST- 2007/01/11 00:00 [accepted]
PHST- 2007/03/29 09:00 [pubmed]
PHST- 2007/10/24 09:00 [medline]
PHST- 2007/03/29 09:00 [entrez]
AID - 000101437 [pii]
AID - 10.1159/000101437 [doi]
PST - ppublish
SO  - Respiration. 2007;74(5):558-64. doi: 10.1159/000101437. Epub 2007 Mar 27.